TGFBR2

Across TCGA pan-cancer cohorts, TGFBR2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of TGFBR2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where TGFBR2 RNA is repressed in tumor relative to normal tissue. In most cancer types TGFBR2 is over-expressed in tumor, although a few such as BLCA and LUSC show the opposite, repressed pattern.

BLCA, LUSC, and LUAD are the cancer types where TGFBR2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TGFBR2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	All	−1.586	<.001	10	view →
LUSC	Female	II,III,IV	−3.017	<.001	9	view →
LUAD	Female	III,IV	−1.844	<.001	9	view →
KIRP	Male	All	−1.189	<.001	9	view →
THCA	All	III,IV	−1.006	<.001	9	view →
KICH	Female	All	−1.786	<.001	7	view →
UCEC	All	All	−2.217	<.001	6	view →
BRCA	All	III,IV	−1.968	<.001	6	view →
HNSC	Female	III,IV	+1.410	.002	4	view →
CHOL	All	All	+1.010	.010	2	view →
PRAD	All	All	−0.555	.001	2	view →
READ	Female	All	−0.703	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

TGFBR2–BLCA

Open the BLCA breakdown →